166 related articles for article (PubMed ID: 31905926)
21. Inhibition of CD133 Overcomes Cisplatin Resistance Through Inhibiting PI3K/AKT/mTOR Signaling Pathway and Autophagy in CD133-Positive Gastric Cancer Cells.
Lu R; Zhao G; Yang Y; Jiang Z; Cai J; Hu H
Technol Cancer Res Treat; 2019 Jan; 18():1533033819864311. PubMed ID: 31405336
[TBL] [Abstract][Full Text] [Related]
22. DNA-PKcs deficiency sensitizes the human hepatoma HepG2 cells to cisplatin and 5-fluorouracil through suppression of the PI3K/Akt/NF-κB pathway.
Fang Y; Chai Z; Wang D; Kuang T; Wu W; Lou W
Mol Cell Biochem; 2015 Jan; 399(1-2):269-78. PubMed ID: 25348361
[TBL] [Abstract][Full Text] [Related]
23. PEA‑15 contributes to the clinicopathology and AKT‑regulated cisplatin resistance in gastric cancer.
Jiang X; Zhang C; Li W; Jiang D; Wei Z; Lv M; Xie X; Sun X
Oncol Rep; 2019 Mar; 41(3):1949-1959. PubMed ID: 30569123
[TBL] [Abstract][Full Text] [Related]
24. Oxaliplatin in treatment of the cisplatin-resistant MKN45 cell line of gastric cancer.
Tozawa K; Oshima T; Kobayashi T; Yamamoto N; Hayashi C; Matsumoto T; Miwa H
Anticancer Res; 2008; 28(4B):2087-92. PubMed ID: 18751380
[TBL] [Abstract][Full Text] [Related]
25. MiR-129 reduces CDDP resistance in gastric cancer cells by inhibiting MAPK3.
Cao HY; Xiao CH; Lu HJ; Yu HZ; Hong H; Guo CY; Yuan JF
Eur Rev Med Pharmacol Sci; 2019 Aug; 23(15):6478-6485. PubMed ID: 31378887
[TBL] [Abstract][Full Text] [Related]
26. Ubenimex induces autophagy inhibition and EMT suppression to overcome cisplatin resistance in GC cells by perturbing the CD13/EMP3/PI3K/AKT/NF-κB axis.
Guo Q; Jing FJ; Xu W; Li X; Li X; Sun JL; Xing XM; Zhou CK; Jing FB
Aging (Albany NY); 2019 Dec; 12(1):80-105. PubMed ID: 31895687
[TBL] [Abstract][Full Text] [Related]
27. Calycosin Enhances Some Chemotherapeutic Drugs Inhibition of Akt Signaling Pathway in Gastric Cells.
Zhou L; Wu Y; Guo Y; Li Y; Li N; Yang Y; Qin X
Cancer Invest; 2017 May; 35(5):289-300. PubMed ID: 28368679
[TBL] [Abstract][Full Text] [Related]
28. Changes in survivin messenger RNA level during cisplatin treatment in gastric cancer.
Ikeguchi M; Kaibara N
Int J Mol Med; 2001 Dec; 8(6):661-6. PubMed ID: 11712083
[TBL] [Abstract][Full Text] [Related]
29. TAB3 overexpression promotes cell proliferation in non-small cell lung cancer and mediates chemoresistance to CDDP in A549 cells via the NF-κB pathway.
Chen J; Gu J; Feng J; Liu Y; Xue Q; Ni T; Wang Z; Jia L; Mao G; Ji L
Tumour Biol; 2016 Mar; 37(3):3851-61. PubMed ID: 26476534
[TBL] [Abstract][Full Text] [Related]
30. miR-1271 regulates cisplatin resistance of human gastric cancer cell lines by targeting IGF1R, IRS1, mTOR, and BCL2.
Yang M; Shan X; Zhou X; Qiu T; Zhu W; Ding Y; Shu Y; Liu P
Anticancer Agents Med Chem; 2014; 14(6):884-91. PubMed ID: 24875127
[TBL] [Abstract][Full Text] [Related]
31. Repression of GRIM19 expression potentiates cisplatin chemoresistance in advanced bladder cancer cells via disrupting ubiquitination-mediated Bcl-xL degradation.
Ni F; Yan CY; Zhou S; Hui PY; Du YH; Zheng L; Yu J; Hu XJ; Zhang ZG
Cancer Chemother Pharmacol; 2018 Oct; 82(4):593-605. PubMed ID: 30032449
[TBL] [Abstract][Full Text] [Related]
32. Adenovirus-mediated IL-24 expression enhances the chemosensitivity of multidrug-resistantgastric cancer cells to cisplatin.
Mao Z; Bian G; Sheng W; He S; Yang J; Dong X
Oncol Rep; 2013 Nov; 30(5):2288-96. PubMed ID: 23982423
[TBL] [Abstract][Full Text] [Related]
33. Androgen receptor activity modulates responses to cisplatin treatment in bladder cancer.
Kashiwagi E; Ide H; Inoue S; Kawahara T; Zheng Y; Reis LO; Baras AS; Miyamoto H
Oncotarget; 2016 Aug; 7(31):49169-49179. PubMed ID: 27322140
[TBL] [Abstract][Full Text] [Related]
34. Akt confers cisplatin chemoresistance in human gynecological carcinoma cells by modulating PPM1D stability.
Ali AY; Kim JY; Pelletier JF; Vanderhyden BC; Bachvarov DR; Tsang BK
Mol Carcinog; 2015 Nov; 54(11):1301-14. PubMed ID: 25154814
[TBL] [Abstract][Full Text] [Related]
35. [Wogonoside reverses cisplatin resistance in SGC7901/cDDP cells through inhibition of PI3K/Akt/Nrf2/ARE signaling pathway].
Wang LJ; Wang SG; Deng TX
Sheng Li Xue Bao; 2018 Aug; 70(4):397-405. PubMed ID: 30112565
[TBL] [Abstract][Full Text] [Related]
36. Omega-3 Polyunsaturated Fatty Acids Enhance Cisplatin Efficacy in Gastric Cancer Cells by Inducing Apoptosis via ADORA1.
Sheng H; Chen X; Liu B; Li P; Cao W
Anticancer Agents Med Chem; 2016; 16(9):1085-92. PubMed ID: 27025656
[TBL] [Abstract][Full Text] [Related]
37. Knockdown of long non-coding RNA HOTAIR inhibits cisplatin resistance of gastric cancer cells through inhibiting the PI3K/Akt and Wnt/β-catenin signaling pathways by up-regulating miR-34a.
Cheng C; Qin Y; Zhi Q; Wang J; Qin C
Int J Biol Macromol; 2018 Feb; 107(Pt B):2620-2629. PubMed ID: 29080815
[TBL] [Abstract][Full Text] [Related]
38. The effects and mechanism of α-mangostin on chemosensitivity of gastric cancer cells.
Li RR; Zeng DY
Kaohsiung J Med Sci; 2021 Aug; 37(8):709-717. PubMed ID: 34003591
[TBL] [Abstract][Full Text] [Related]
39. HMGB1 was negatively regulated by HSF1 and mediated the TLR4/MyD88/NF-κB signal pathway in asthma.
Shang L; Wang L; Shi X; Wang N; Zhao L; Wang J; Liu C
Life Sci; 2020 Jan; 241():117120. PubMed ID: 31825792
[TBL] [Abstract][Full Text] [Related]
40. Notch pathway inhibition using DAPT, a γ-secretase inhibitor (GSI), enhances the antitumor effect of cisplatin in resistant osteosarcoma.
Dai G; Deng S; Guo W; Yu L; Yang J; Zhou S; Gao T
Mol Carcinog; 2019 Jan; 58(1):3-18. PubMed ID: 29964327
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]